1stOncology™: Cancer Intelligence Service – Page 12017 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference

On November 26, 2019 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported that it will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 8:20 a.m. ET in Boston, MA (Press release, Intellia Therapeutics, NOV 26, 2019, http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-present-evercore-isi-2nd-annual-healthconx [SID1234551703]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast of Intellia’s presentation will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcast, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for approximately 14 days following each conference.

ImmunoGen Announces Webcast of Presentation at the Piper Jaffray 31st Annual Healthcare Conference

On November 26, 2019 ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that the Company will participate in a fireside chat at the upcoming Piper Jaffray Healthcare Conference (Press release, ImmunoGen, NOV 26, 2019, View Source [SID1234551702]). The fireside chat is scheduled for 12:30 p.m. ET on December 3, 2019.

A webcast of the fireside chat will be accessible live through the "Investors & Media" section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.

Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference

On November 26, 2019 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Evercore ISI HealthCONx Conference on Tuesday, December 3, 2019 at 12:05 p.m. EST at the Four Seasons hotel in Boston, MA (Press release, Heron Therapeutics, NOV 26, 2019, https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-present-evercore-isi-healthconx-conference-0 [SID1234551701]).

A live webcast of the presentation will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

ExCellThera announces clinical data to be presented at the American Society of Hematology 2019 annual meeting

On November 26, 2019 ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, reported that data from a Phase I/II clinical trial using its lead technology, ECT-001, will be presented at the 61st Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) in Orlando, Florida (Press release, ExCellThera, NOV 26, 2019, View Source [SID1234551699]). Details of the presentation are as follows:

Date & Time: Sunday, December 8, 2019; 6:00-8:00 p.m. ET
Title: UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies
Abstract Number: 3245
Lead Author: Sandra Cohen, MD, FRCP(C), Division of Hematology and Medical Oncology, Stem Cell Transplant Program, Department of Medicine, University of Montreal and Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
Location: Orange County Convention Center, Hall B

About ECT-001
The ECT-001 technology is a combination of a small molecule, UM171, and an optimized culture system. The technology, capable of expanding the number of stem and immune cells exponentially in as little as seven days, is used in novel curative cord blood transplant therapies for patients with blood cancers, allowing rapid engraftment, greatly reduced incidence of transplant-related mortality, low risk of chronic graft-versus-host disease and low risk of relapse, resulting in better outcomes for patients.

Axial Biotherapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

On November 26, 2019 Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, reported that the company will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 1:10 PM ET in New York, NY (Press release, Axial Biotherapeutics, NOV 26, 2019, View Source [SID1234551697]).